Spero Therapeutics, Inc. (SPRO) Total Assets by Year
Spero Therapeutics, Inc. closed fiscal year 2025 with $68.9M in total assets, $9.9M in total liabilities and $59.0M in shareholder equity. This represents a decrease of 37.7% from the prior fiscal year. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Spero Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
SPRO Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $68.9M-37.7% | $110.5M-39.4% | $182.4M+46.1% | $124.8M-27.0% | $171.1M+11.5% | $153.5M+44.6% | $106.1M-17.8% | $129.0M+38.0% | $93.5M+578.8% | $13.8M | N/A |
| Total Liabilities | $9.9M-84.6% | $64.4M-14.7% | $75.5M+54.5% | $48.9M-41.0% | $82.8M+286.6% | $21.4M-32.1% | $31.5M+139.7% | $13.2M+54.3% | $8.5M-85.6% | $59.2M | N/A |
| Total Equity | $59.0M+28.0% | $46.1M-56.9% | $106.9M+40.8% | $75.9M-14.0% | $88.3M-33.1% | $132.0M+77.1% | $74.6M-35.4% | $115.5M+36.5% | $84.6M+286.2% | -$45.4M-144.9% | -$18.6M |
SPRO Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $52.8M-15.1% | $59.0M-24.0% | $68.9M-37.7% | $54.2M-59.9% | $62.1M-58.6% | $77.7M-53.7% | $110.5M-39.4% | $135.2M+26.2% | $149.9M+51.6% | $167.7M+49.0% | $182.4M+46.1% | $107.1M+66.1% |
| Total Liabilities | $8.6M-70.8% | $6.1M-86.1% | $9.9M-84.6% | $27.7M-60.3% | $29.3M-57.8% | $43.9M-38.6% | $64.4M-14.7% | $69.7M+30.4% | $69.4M+57.3% | $71.5M+49.8% | $75.5M+54.5% | $53.4M+66.9% |
| Total Equity | $44.2M+34.7% | $52.9M+56.5% | $59.0M+28.0% | $26.5M-59.6% | $32.8M-59.2% | $33.8M-64.9% | $46.1M-56.9% | $65.5M+22.0% | $80.5M+46.9% | $96.2M+48.4% | $106.9M+40.8% | $53.7M+65.3% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Spero Therapeutics, Inc. financials
Frequently Asked Questions
What was Spero Therapeutics, Inc.'s total assets in fiscal year 2025?
Spero Therapeutics, Inc. closed fiscal year 2025 with $68.9M in total assets, $9.9M in total liabilities and $59.0M in shareholder equity.
How fast is Spero Therapeutics, Inc.'s total assets growing?
Spero Therapeutics, Inc. (SPRO) total assets fell by 37.7% year over year, from $110.5M to $68.9M in fiscal year 2025.
What was Spero Therapeutics, Inc.'s total assets in the most recent quarter?
Spero Therapeutics, Inc. (SPRO) reported $52.8M in total assets in Q2 2026. This represents a decrease of 15.1% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Spero Therapeutics, Inc. (SPRO) reported on that line in every period on record.